article thumbnail

Opinion: STAT+: It’s time to rethink everything about our approach to psychiatric drug development

STAT

Despite significant efforts, progress in psychiatric drug development has remained disappointingly slow. But the landscape remains predominantly marked by failures and a dry drug development pipeline. Approved drugs follow the same pattern of prescribing via guesswork, with most patients not responding to a given drug.

article thumbnail

STAT+: Drug development was once a marathon. New tools and timelines are turning it into a sprint

STAT

Drug development is more of a sprint than a marathon these days, thanks to more and better ways to target underlying biology and a more nuanced interpretation of precision medicine, three biotech leaders said at the STAT Breakthrough Summit East in New York Thursday.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: The ADC hot streak continues: J&J to buy cancer drug developer Ambrx Biopharma

STAT

Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development.     The deal, disclosed as the biopharma field marked the first day of the annual J.P.

article thumbnail

Transforming drug development with AI

pharmaphorum

Discover how artificial intelligence (AI) is revolutionising the drug development process and transforming the way FDA-approved drugs are produced, ensuring compliance and optimising the supply chain. Learn more about the future of AI in pharmaceuticals.

article thumbnail

STAT+: In drug development, large pharma companies’ staying power provides them an edge, Lilly’s chief medical officer says

STAT

But at the STAT Summit on Wednesday, Daniel Skovronsky, the chief scientific and medical officer at Eli Lilly, discussed how Lilly has been able to crack both obesity and Alzheimer’s , two areas that have long stumped drug developers, and now two of the hottest commercial opportunities.

article thumbnail

Believe the hype? Mixed signals from AI’s impact on drug development

PharmaVoice

Although AI’s failure rates in drug development still leave room for improvement, today’s missteps feed tomorrow’s successes.

article thumbnail

STAT+: Nektar Therapeutics sues Lilly for ‘misconduct’ in drug development deal

STAT

A behind-the-scenes feud over a drug development program erupted into public view as Nektar Therapeutics filed a lawsuit accusing Eli Lilly of undermining a project in favor of another deal.